These are top 10 stocks traded on the Robinhood UK platform in July
Eiry Roberts, Chief Medical (TASE:PMCN) Officer of Neurocrine Biosciences Inc. (NASDAQ:NBIX), executed a series of stock transactions earlier this month, according to a recent SEC filing. The transactions come as the $11.4 billion biopharmaceutical company's stock trades near its 52-week low of $110.95, with InvestingPro data indicating oversold conditions. On February 13 and 14, Roberts sold a total of 2,218 shares of common stock, generating proceeds of approximately $258,263.
The sales were part of a pre-established trading plan and included 1,114 shares sold at a weighted average price of $116.90, 604 shares at $116.73, and 500 shares at $115.04. These transactions reduced Roberts' direct ownership to 35,640 shares following the sales. According to InvestingPro analysis, analyst price targets suggest potential upside, with targets ranging from $138 to $192.
In addition to the sales, Roberts acquired shares through option exercises and restricted stock units, although these acquisitions were valued at zero per share. The transactions reflect Roberts' ongoing management of her equity holdings in the company, which maintains strong financial health with a current ratio of 3.4 and operates with moderate debt levels. For deeper insights into Neurocrine's financial metrics and additional ProTips, visit InvestingPro.
In other recent news, Neurocrine Biosciences has been a focal point for several analysts. Deutsche Bank (ETR:DBKGn) initiated coverage on the company, assigning a Hold rating with a price target of $138. They believe the company's stock is fairly valued given its current market capitalization and the prospects of its Ingrezza and Crensessity treatments. UBS, however, maintained a Buy rating while reducing the price target to $154, citing a more conservative growth trajectory for Ingrezza.
Guggenheim also maintained a Buy rating but cut the price target to $163 following the company's fourth-quarter sales report, which showed slightly lower than expected Ingrezza sales. H.C. Wainwright echoed this sentiment, maintaining a Buy rating but lowering the price target to $185 due to lower-than-expected full-year 2025 Ingrezza revenue guidance.
These recent developments reflect differing analyst views on the company's potential, with a common focus on the performance of Ingrezza and the future prospects of Crenessity. Despite these varied perspectives, all analysts seem to agree on the importance of Neurocrine Biosciences' ongoing clinical pipeline and the potential impact of future treatments under development.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.